View in EDS

MO45-1 Osimertinib vs. erlotinib + bevacizumab or ramucirumab for EGFR mutated NSCLC; a retrospective study from LC-SCRUM-Asia.

Saved in:
Bibliographic Details
Title: MO45-1 Osimertinib vs. erlotinib + bevacizumab or ramucirumab for EGFR mutated NSCLC; a retrospective study from LC-SCRUM-Asia.
Authors: Kagawa, Yosuke1 (AUTHOR), Nosaki, Kaname1 (AUTHOR), Matsumoto, Shingo1 (AUTHOR), Kato, Terufumi2 (AUTHOR), Nakamura, Atushi3 (AUTHOR), Shingyoji, Masato4 (AUTHOR), Nishino, Kazumi5 (AUTHOR), Tabata, Eriko6 (AUTHOR), Furuya, Naoki7 (AUTHOR), Miyamoto, Shingo8 (AUTHOR), Sakakibara, Jun9 (AUTHOR), Nakao, Mika10 (AUTHOR), Daga, Haruko11 (AUTHOR), Sakai, Tetsuya1 (AUTHOR), Shibata, Yuji1 (AUTHOR), Izumi, Hiroki1 (AUTHOR), Udagawa, Hibiki1 (AUTHOR), Zenke, Yoshitaka1 (AUTHOR), Yoh, Kiyotaka1 (AUTHOR), Goto, Koichi1 (AUTHOR)
Source: Annals of Oncology. 2022 Supplement 6, Vol. 33, pS510-S510. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2022.05.214